The Feasibility and Validity of Prokinetic Prescription in Children with Chronic Gastroduodenal Pathology and Lesions of the Pancreas

Z.V. Tomkiv, V.V. Kunovskyy

Abstract

On the example of treating 49 children from 8 to 17 years old with chronic gastroduodenal diseases (20 children with chronic gastroduodenitis, 14 — with erosive gastroduodenitis and 15 — with gastroduodenal ulcer) and concomitant changes in the pancreas, we considered the feasibility of inclusion in comprehensive drug treatment of motility stimulants (Brulium linguatabs prokinetic). Adding to the basic therapy of Brulium linguatabs prokinetic is due to the presence in these patients of violations in motor-evacuation function of the duodenum and associated duodenostasis syndrome, because increase pressure in the lumen of the duodenum impairs the outflow from the common bile duct and pancreatic duct, which greatly increases the risk of duodenopancreatic reflux. It is found that 87 % of main group patients, starting from the third day of treatment, reported significant (p < 0.05) manifestations of gastrointestinal motility normalization, leveling the symptoms of nausea and vomiting (average score of nausea decreased up to 1.4 vs 3.0, and vomiting — up to 1.0 vs 2.6), improved appetite.